Hydraderm for Androgenic Alopecia

Launched by UNIVERSITY OF MINNESOTA · Jun 20, 2022

Keywords

ClinConnect Summary

This clinical trial, called "Hydraderm for Androgenic Alopecia," is investigating a treatment called hydradermabrasion for people experiencing hair loss due to androgenic alopecia, a common type of hair thinning. The goal of the study is to see how this treatment affects the health of the scalp and promotes hair growth. The trial is currently looking for participants aged 18 to 65 who have been diagnosed with androgenetic alopecia and are willing to follow specific study guidelines, including continuing their current hair loss treatment and using the same shampoo throughout the study.

If you join this trial, you will attend regular visits and may be photographed for research purposes. It’s important to note that participants should not have had any changes to their hair loss treatment within the last four months and must be free from certain skin conditions or infections on the scalp. The study aims to provide valuable information about new ways to improve scalp health and hair growth, and your participation could help advance knowledge in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who can give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA Authorization
• • Participants who have androgenetic alopecia
• • Healthy men and women, ages 18 - 65 years of age
• • Participants who understand the study and can follow study instructions and are willing to attend the required study visits
• • Participants who agree to be photographed for research purposes and their identity may not be concealed in these photographs.
• • Participants who agree to continue their same treatment they are on at the baseline visit for androgenetic alopecia, for the entire duration of the study without plans to stop, change or add additional treatments.
• • Participants who agree to use the same shampoo for the duration of the study
• Exclusion Criteria:
• • Participants who have not had a change to hair loss treatment for 4 months prior to study enrollment
• • Participants who have an active or known skin inflammation or infection within the treatment area.
• • Participants who have an active or known acute skin allergies
• • Participants who have any other scalp conditions including eczema, psoriasis, infection, or scars within the treatment area
• • Participants of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy, or bilateral oophorectomy.
• • Participants who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy.
• • Immunosuppression
• • Participants who are HIV+ / Hepatitis B + / Hepatitis C+
• • Participants who have been diagnosed or have a known history of any hematopathology disorders
• • Participants who have been diagnosed or have a known history of haemostasis disorders
• • Participants who have been diagnosed or have a known history of an autoimmune diseases
• • Participants who are undergoing chemotherapy
• • Participants with a history of any skin cancer on the scalp
• • Participants who have had skin biopsy or procedure on scalp in last month
• • Participants who have an implantable devices such as a deep brain stimulator in or other implantable device on or near treatment area
• • Non-English speakers